Intellia reported Phase 3 success for its in vivo CRISPR medicine lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE), meeting the primary endpoint by reducing swelling attack rates 87% versus placebo at six months. Just over 60% of patients were attack-free during the study period, positioning the therapy as a potential functional cure approach rather than chronic prophylaxis. The company said it has initiated regulatory steps, including a rolling submission with the FDA, with the intent to bring a one-time, in-body gene-editing therapy to market. The Phase 3 HAELO study was designed around clinical attack endpoints, giving a clear efficacy signal directly tied to patient symptoms. Intellia’s result is a market-test case for whether durable in vivo editing benefits can outweigh longer-term concerns about permanent genetic changes, and it raises expectations for how regulators will evaluate safety across edited tissues over time.